Eagle Pharmaceuticals Company Profile (NASDAQ:EGRX)

About Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals logoEagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EGRX
  • CUSIP: N/A
  • Web: www.eagleus.com
Capitalization:
  • Market Cap: $1.15043 billion
  • Outstanding Shares: 15,298,000
Average Prices:
  • 50 Day Moving Avg: $76.50
  • 200 Day Moving Avg: $77.91
  • 52 Week Range: $42.33 - $97.15
P/E:
  • Trailing P/E Ratio: 11.44
  • Foreward P/E Ratio: 15.10
  • P/E Growth: 1.37
Sales & Book Value:
  • Annual Revenue: $236.68 million
  • Price / Sales: 4.71
  • Book Value: $10.94 per share
  • Price / Book: 6.65
Profitability:
  • EBIDTA: $90.92 million
  • Net Margins: 44.48%
  • Return on Equity: 79.25%
  • Return on Assets: 57.28%
Debt:
  • Current Ratio: 3.49%
  • Quick Ratio: 3.40%
Misc:
  • Average Volume: 361,162 shs.
  • Beta: 1.48
  • Short Ratio: 8.36
 
Frequently Asked Questions for Eagle Pharmaceuticals (NASDAQ:EGRX)

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced its earnings results on Monday, May, 8th. The company reported $1.42 EPS for the quarter, missing the consensus estimate of $1.44 by $0.02. The company had revenue of $76.80 million for the quarter, compared to analysts' expectations of $70.10 million. Eagle Pharmaceuticals had a net margin of 44.48% and a return on equity of 79.25%. The business's quarterly revenue was up 159.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.06) earnings per share. View Eagle Pharmaceuticals' Earnings History.

Where is Eagle Pharmaceuticals' stock going? Where will Eagle Pharmaceuticals' stock price be in 2017?

4 brokers have issued 12-month target prices for Eagle Pharmaceuticals' stock. Their predictions range from $57.00 to $118.00. On average, they anticipate Eagle Pharmaceuticals' stock price to reach $91.50 in the next twelve months. View Analyst Ratings for Eagle Pharmaceuticals.

What are analysts saying about Eagle Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (7/10/2017)
  • 2. Mizuho analysts commented, "We remain cautious on 2017 revenue, the exertional heat stroke (EHS) launch, and lower takeout probability: Eagle reported 4Q:16 revs of $81.1M and GAAP EPS of $3.52 vs. FactSet consensus $86.0M and $2.82. Mgmt introduced FY:17 SG&A guidance of $65-$68M and $31-$35M in R&D. Consensus models are in line with these expense ranges, but we think that 2017 revenue expectations (particularly Ryanodex) need to come down based on a slower EHS ramp. Because we now have a better appreciation for the hurdles associated with this launch, we also lowered our probability of takeout to 40%, from 50% previously. On a standalone basis, we think that EGRX is only worth $54/share so the stock already reflects expectations of a takeout, in our view. We reiterate our Underperform rating and $66 PT, which are based on a weighted blend of DCF ($54) and SOTP ($85) valuations." (3/17/2017)

Who are some of Eagle Pharmaceuticals' key competitors?

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the folowing people:

  • Michael Graves, Independent Chairman of the Board
  • Scott L. Tarriff, Chief Executive Officer, Independent Director
  • Pete A. Meyers, Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
  • David E. Riggs, Chief Financial Officer
  • Steven L. Krill Ph.D., Executive Vice President, Chief Scientific Officer
  • Adrian J. Hepner M.D. Ph.D, Executive Vice President, Chief Medical Officer
  • Douglas L. Braunstein, Independent Director
  • Richard A. Edlin, Independent Director
  • Sander A. Flaum, Independent Director
  • Robert L. Glenning, Independent Director

Who owns Eagle Pharmaceuticals stock?

Eagle Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Hershey Trust Co. (0.10%), James Investment Research Inc. (0.09%), Fisher Asset Management LLC (0.07%), Aperio Group LLC (0.02%), Louisiana State Employees Retirement System (0.02%) and Capstone Asset Management Co. (0.02%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Michael Graves, Pete A Meyers, Proquest Investments Iv, LP, Proquest Management Llc, Richard A Edlin, Sander A Flaum, Sander A Flaum, Scott Tarriff, Steven B Ratoff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.

Who sold Eagle Pharmaceuticals stock? Who is selling Eagle Pharmaceuticals stock?

Eagle Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Capstone Asset Management Co. and Louisiana State Employees Retirement System. Company insiders that have sold Eagle Pharmaceuticals stock in the last year include Proquest Investments Iv, LP, Sander A Flaum, Steven B Ratoff and Steven L Krill. View Insider Buying and Selling for Eagle Pharmaceuticals.

Who bought Eagle Pharmaceuticals stock? Who is buying Eagle Pharmaceuticals stock?

Eagle Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Hershey Trust Co., James Investment Research Inc., Aperio Group LLC, Fisher Asset Management LLC, Bank of Montreal Can and State of Alaska Department of Revenue. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Michael Graves, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.

How do I buy Eagle Pharmaceuticals stock?

Shares of Eagle Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eagle Pharmaceuticals' stock price today?

One share of Eagle Pharmaceuticals stock can currently be purchased for approximately $72.80.


MarketBeat Community Rating for Eagle Pharmaceuticals (NASDAQ EGRX)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  204 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  295
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Eagle Pharmaceuticals (NASDAQ:EGRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $91.50 (25.69% upside)

Analysts' Ratings History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/16/2017Royal Bank Of CanadaSet Price TargetBuy$94.00MediumView Rating Details
5/25/2017MizuhoLower Price TargetUnderperform$66.00 -> $57.00LowView Rating Details
5/9/2017Piper Jaffray CompaniesSet Price TargetOverweight$90.00 -> $118.00HighView Rating Details
11/2/2016William BlairBoost Price TargetOutperform$83.00 -> $97.00N/AView Rating Details
(Data available from 7/25/2015 forward)

Earnings

Earnings History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Earnings by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)
Earnings History by Quarter for Eagle Pharmaceuticals (NASDAQ EGRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017$1.44$1.42$70.10 million$76.80 millionViewListenView Earnings Details
3/1/2017Q416$2.24$3.52$86.13 million$81.10 millionViewListenView Earnings Details
11/9/2016Q316$0.71$0.73$41.04 million$37.80 millionViewListenView Earnings Details
8/9/2016Q216$0.71$0.80$43.55 million$40.90 millionViewN/AView Earnings Details
5/9/2016Q116$0.46($0.06)$29.07 million$29.60 millionViewN/AView Earnings Details
2/25/2016Q415$0.53$0.07$20.78 million$18.20 millionViewListenView Earnings Details
11/11/2015Q315($0.56)($0.65)$5.07 million$3.30 millionViewListenView Earnings Details
8/11/2015Q215($0.59)($0.53)$4.70 million$6.00 millionViewListenView Earnings Details
5/12/2015Q115$1.56$1.31$3.41 million$36.30 millionViewListenView Earnings Details
12/17/2014Q314($0.49)($0.65)$2.90 million$2.81 millionViewN/AView Earnings Details
8/11/2014Q214($0.39)($0.21)$3.40 million$5.80 millionViewN/AView Earnings Details
5/14/2014Q114($0.26)($0.36)$3.20 million$5.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eagle Pharmaceuticals (NASDAQ:EGRX)
2017 EPS Consensus Estimate: $3.83
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$1.46$1.46$1.46
Q2 20171$0.59$0.59$0.59
Q3 20171$0.68$0.68$0.68
Q4 20171$1.10$1.10$1.10
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Eagle Pharmaceuticals (NASDAQ:EGRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Insider Ownership Percentage: 19.50%
Insider Trades by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)
Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)
Insider Trades by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/12/2017Pete A MeyersCFOBuy350$71.49$25,021.50View SEC Filing  
5/19/2017David PernockInsiderBuy255$79.69$20,320.95View SEC Filing  
5/16/2017David PernockInsiderBuy200$82.24$16,448.00View SEC Filing  
4/25/2017Proquest Investments Iv, L.P.Major ShareholderSell54,180$88.38$4,788,428.40View SEC Filing  
4/3/2017Proquest Investments Iv, L.P.Major ShareholderSell91,332$83.09$7,588,775.88View SEC Filing  
3/29/2017Proquest Investments Iv, L.P.Major ShareholderSell106,468$83.01$8,837,908.68View SEC Filing  
3/28/2017Proquest Investments Iv, L.P.Major ShareholderSell6,182$83.02$513,229.64View SEC Filing  
3/27/2017Proquest Investments Iv, L.P.Major ShareholderSell39,431$83.00$3,272,773.00View SEC Filing  
3/23/2017Proquest Investments Iv, L.P.Major ShareholderSell1,200$83.05$99,660.00View SEC Filing  
3/23/2017Steven L KrillEVPSell14,125$81.07$1,145,113.75View SEC Filing  
3/22/2017Richard A EdlinDirectorBuy6,000$79.44$476,640.00View SEC Filing  
3/21/2017David PernockInsiderBuy61$83.98$5,122.78View SEC Filing  
3/20/2017Proquest Investments Iv, L.P.Major ShareholderSell100,000$82.06$8,206,000.00View SEC Filing  
3/9/2017David PernockInsiderBuy450$77.84$35,028.00View SEC Filing  
1/4/2017Proquest Investments Iv, L.P.Major ShareholderSell65,114$85.16$5,545,108.24View SEC Filing  
12/13/2016Steven B RatoffDirectorSell10,000$75.01$750,100.00View SEC Filing  
11/28/2016Sander A FlaumDirectorSell5,000$78.66$393,300.00View SEC Filing  
11/11/2016Proquest Investments Iv, L.P.Major ShareholderSell34,486$85.15$2,936,482.90View SEC Filing  
11/9/2016Proquest Investments Iv, L.P.Major ShareholderSell153,830$79.29$12,197,180.70View SEC Filing  
11/7/2016Proquest Investments Iv, L.P.Major ShareholderSell5,030$75.39$379,211.70View SEC Filing  
11/4/2016Proquest Investments Iv, L.P.Major ShareholderSell245,770$71.02$17,454,585.40View SEC Filing  
9/30/2016Proquest Investments Iv, L.P.Major ShareholderSell22,100$70.06$1,548,326.00View SEC Filing  
9/29/2016Proquest Investments Iv, L.P.Major ShareholderSell77,900$70.04$5,456,116.00View SEC Filing  
9/21/2016Proquest Investments Iv, L.P.Major ShareholderSell99,795$66.17$6,603,435.15View SEC Filing  
9/8/2016Proquest Investments Iv, L.P.Major ShareholderSell70,925$62.50$4,432,812.50View SEC Filing  
8/24/2016Proquest Investments Iv, L.P.Major ShareholderSell28,870$63.00$1,818,810.00View SEC Filing  
8/17/2016Proquest Investments Iv, L.P.Major ShareholderSell99,795$61.36$6,123,421.20View SEC Filing  
8/16/2016Proquest Investments Iv, L.P.Major ShareholderSell60,150$61.67$3,709,450.50View SEC Filing  
8/15/2016Proquest Investments Iv, L.P.Major ShareholderSell24,949$60.77$1,516,150.73View SEC Filing  
5/13/2016Proquest Management LlcMajor ShareholderSell17,980$40.72$732,145.60View SEC Filing  
4/1/2016Scott TarriffCEOSell30,765$40.63$1,249,981.95View SEC Filing  
3/15/2016Michael GravesDirectorBuy1,000$56.73$56,730.00View SEC Filing  
2/1/2016Scott TarriffCEOSell18,360$68.08$1,249,948.80View SEC Filing  
12/22/2015Sander A. FlaumDirectorSell13,025$54.81$713,900.25View SEC Filing  
12/1/2015Scott TarriffCEOSell14,050$88.93$1,249,466.50View SEC Filing  
11/2/2015Scott TarriffCEOSell19,339$64.63$1,249,879.57View SEC Filing  
10/1/2015Scott TarriffCEOSell17,878$69.92$1,250,029.76View SEC Filing  
9/1/2015Scott TarriffCEOSell16,245$76.95$1,250,052.75View SEC Filing  
7/1/2015Scott TarriffCEOSell135,710$46.34$6,288,801.40View SEC Filing  
6/16/2015Steven L KrillInsiderSell9,980$81.60$814,368.00View SEC Filing  
2/18/2014Jay MoorinDirectorBuy333,333$15.00$4,999,995.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Eagle Pharmaceuticals (NASDAQ:EGRX)
Latest Headlines for Eagle Pharmaceuticals (NASDAQ:EGRX)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Eagle Pharmaceuticals, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 6:04 PM
americanbankingnews.com logoEagle Pharmaceuticals Inc (EGRX) Given a $94.00 Price Target at Royal Bank Of Canada
www.americanbankingnews.com - July 18 at 12:56 AM
finance.yahoo.com logoETFs with exposure to Eagle Pharmaceuticals, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 3:31 PM
finance.yahoo.com logoEagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : July 11, 2017
finance.yahoo.com - July 11 at 7:20 PM
americanbankingnews.com logoEagle Pharmaceuticals, Inc. (EGRX) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - July 10 at 8:26 PM
seekingalpha.com logoEagle Pharmaceuticals' Upcoming Catalysts Provide Support For Medium-Term Play
seekingalpha.com - July 8 at 10:28 AM
americanbankingnews.com logoContrasting Eagle Pharmaceuticals (NASDAQ:EGRX) & Mallinckrodt PLC (MNK)
www.americanbankingnews.com - July 6 at 7:40 AM
247wallst.com logoTop Stocks to Look For on July’s FDA Calendar
247wallst.com - July 1 at 5:49 PM
americanbankingnews.com logoEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - June 30 at 11:32 PM
americanbankingnews.com logoEagle Pharmaceuticals, Inc. (EGRX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 30 at 12:32 PM
finance.yahoo.com logoEagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : June 26, 2017
finance.yahoo.com - June 26 at 9:37 AM
finance.yahoo.com logoThese 3 Stocks Are Up Over 500% in the Last 3 Years
finance.yahoo.com - June 25 at 5:36 PM
americanbankingnews.com logoEagle Pharmaceuticals, Inc. (EGRX) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - June 21 at 7:32 PM
finance.yahoo.com logoETFs with exposure to Eagle Pharmaceuticals, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 6:33 PM
nasdaq.com logoEagle Pharmaceuticals (EGRX) Shares Cross Above 200 DMA
www.nasdaq.com - June 19 at 1:33 PM
finance.yahoo.com logoEagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 5:46 PM
americanbankingnews.com logoInsider Buying: Eagle Pharmaceuticals, Inc. (EGRX) CFO Acquires 350 Shares of Stock
www.americanbankingnews.com - June 12 at 7:52 PM
nasdaq.com logoWhat Falling Estimates & Price Mean for Eagle Pharmaceuticals (EGRX) - Nasdaq
www.nasdaq.com - June 8 at 5:55 PM
finance.yahoo.com logoWhat Falling Estimates & Price Mean for Eagle Pharmaceuticals (EGRX)
finance.yahoo.com - June 8 at 5:54 PM
americanbankingnews.com logoEagle Pharmaceuticals Inc (EGRX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - June 5 at 9:15 AM
businesswire.com logoEagle Pharmaceuticals, Inc. to Present at Investor Conferences in June - Business Wire (press release)
www.businesswire.com - June 2 at 3:43 AM
finance.yahoo.com logoEagle Pharmaceuticals, Inc. to Present at Investor Conferences in June
finance.yahoo.com - May 31 at 4:55 PM
nasdaq.com logoEagle Pharmaceuticals (EGRX) Shares Cross Below 200 DMA - Nasdaq
www.nasdaq.com - May 25 at 6:52 PM
americanbankingnews.com logoEagle Pharmaceuticals' (EGRX) Underperform Rating Reaffirmed at Mizuho
www.americanbankingnews.com - May 25 at 6:48 PM
americanbankingnews.com logoEagle Pharmaceuticals Inc (EGRX) Insider Buys $20,320.95 in Stock
www.americanbankingnews.com - May 19 at 8:52 PM
americanbankingnews.com logoEagle Pharmaceuticals Inc (EGRX) Insider Purchases $16,448.00 in Stock
www.americanbankingnews.com - May 16 at 8:44 PM
americanbankingnews.com logoValuEngine Upgrades Eagle Pharmaceuticals Inc (EGRX) to "Strong-Buy"
www.americanbankingnews.com - May 16 at 4:32 PM
rttnews.com logoEagle Pharmaceuticals Inc. (EGRX) Dropped After New CFO Appointed
www.rttnews.com - May 16 at 12:40 PM
finance.yahoo.com logoEagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : May 16, 2017
finance.yahoo.com - May 16 at 12:39 PM
americanbankingnews.com logoEagle Pharmaceuticals Inc (EGRX) Short Interest Update
www.americanbankingnews.com - May 16 at 7:26 AM
nasdaq.com logoEagle Pharmaceuticals Inc. (EGRX) Is Losing Ground After New CFO Named
www.nasdaq.com - May 15 at 11:44 AM
finance.yahoo.com logoEagle Pharmaceuticals Appoints Pete A. Meyers as Chief Financial Officer
finance.yahoo.com - May 15 at 11:44 AM
finance.yahoo.com logoEdited Transcript of EGRX earnings conference call or presentation 8-May-17 12:30pm GMT
finance.yahoo.com - May 12 at 5:24 PM
americanbankingnews.com logoQ2 2017 EPS Estimates for Eagle Pharmaceuticals Inc (EGRX) Decreased by Analyst
www.americanbankingnews.com - May 11 at 8:50 AM
americanbankingnews.com logoEagle Pharmaceuticals Inc (EGRX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 10 at 11:54 PM
finance.yahoo.com logoEagle Pharmaceuticals, Inc. to Present at Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - May 10 at 5:03 PM
americanbankingnews.com logoEagle Pharmaceuticals Inc (EGRX) Forecasted to Post Q3 2017 Earnings of $0.68 Per Share
www.americanbankingnews.com - May 10 at 9:10 AM
americanbankingnews.com logoEagle Pharmaceuticals Inc (EGRX) Receives "Overweight" Rating from Piper Jaffray Companies
www.americanbankingnews.com - May 9 at 8:14 AM
finance.yahoo.com logoEagle Pharmaceuticals, Inc. Reports First Quarter 2017 Results
finance.yahoo.com - May 9 at 7:32 AM
americanbankingnews.com logoEagle Pharmaceuticals Inc (EGRX) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 3:36 PM
businesswire.com logoEagle Pharmaceuticals, Inc. Reports First Quarter 2017 Results - Business Wire (press release)
www.businesswire.com - May 8 at 9:15 AM
nasdaq.com logoCommit To Buy Eagle Pharmaceuticals At $75, Earn 11.3% Annualized Using Options
www.nasdaq.com - May 5 at 5:05 PM
americanbankingnews.com logoEagle Pharmaceuticals (EGRX) Given Daily News Impact Score of 0.22
www.americanbankingnews.com - May 4 at 1:21 AM
americanbankingnews.com logoEagle Pharmaceuticals Inc (EGRX) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - May 3 at 1:01 AM
americanbankingnews.com logoEagle Pharmaceuticals (EGRX) Getting Somewhat Positive Press Coverage, Analysis Shows
www.americanbankingnews.com - April 29 at 2:51 PM
americanbankingnews.com logoInsider Selling: Eagle Pharmaceuticals Inc (EGRX) Major Shareholder Sells 54,180 Shares of Stock
www.americanbankingnews.com - April 27 at 9:03 PM
americanbankingnews.com logoEagle Pharmaceuticals (EGRX) Earns Media Impact Rating of 0.13
www.americanbankingnews.com - April 26 at 5:52 PM
americanbankingnews.com logoEagle Pharmaceuticals Inc (EGRX) PT Set at $86.00 by Royal Bank of Canada
www.americanbankingnews.com - April 25 at 4:18 PM
finance.yahoo.com logoEagle Pharmaceuticals, Inc. to Discuss First Quarter 2017 Financial Results on May 8, 2017
finance.yahoo.com - April 25 at 11:38 AM
finance.yahoo.com logoETFs with exposure to Eagle Pharmaceuticals, Inc. : April 24, 2017
finance.yahoo.com - April 24 at 4:45 PM

Social

Chart

Eagle Pharmaceuticals (EGRX) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by MarketBeat.com Staff